Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains.

Fragment-based ligand discovery has been successful in targeting diverse proteins. Despite drug-like molecules having more 3D character, traditional fragment libraries are largely composed of flat, aromatic fragments. The use of 3D-enriched fragments for enhancing library diversity is underexplored especially against protein-protein interactions. Here, we evaluate using 3D-enriched fragments against bromodomains. Bromodomains are highly ligandable, but selectivity remains challenging, particularly for bromodomain and extraterminal (BET) family bromodomains. We screened a 3D-enriched fragment library against BRD4(D1) via 1H CPMG NMR with a protein-observed 19F NMR secondary assay. The screen led to 29% of the hits that are selective over two related bromodomains, BRDT(D1) and BPTF, and the identification of underrepresented chemical bromodomain inhibitor scaffolds. Initial structure-activity relationship studies guided by X-ray crystallography led to a ligand-efficient thiazepane, with good selectivity and affinity for BET bromodomains. These results suggest that the incorporation of 3D-enriched fragments to increase library diversity can benefit bromodomain screening.

[1]  Miklos Feher,et al.  Fragment Hits: What do They Look Like and How do They Bind? , 2019, Journal of medicinal chemistry.

[2]  Rutger H A Folmer,et al.  Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.

[3]  W. Pomerantz,et al.  Protein-Observed Fluorine NMR Is a Complementary Ligand Discovery Method to 1H CPMG Ligand-Observed NMR. , 2016, ACS chemical biology.

[4]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[5]  H. Wamhoff,et al.  Beiträge zur Chlorierung – Dehydrochlorierung von Perhydro‐1,4‐thiazepin‐5‐onen , 1980 .

[6]  A. Gingras,et al.  Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family , 2012, Cell.

[7]  Ming-Ming Zhou,et al.  Bromodomain biology and drug discovery , 2019, Nature Structural & Molecular Biology.

[8]  Nathan Brown,et al.  Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules , 2012, J. Chem. Inf. Model..

[9]  Nathan Brown,et al.  Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites , 2012, Journal of medicinal chemistry.

[10]  Construction of a Shape-Diverse Fragment Set: Design, Synthesis and Screen against Aurora-A Kinase. , 2019, Chemistry.

[11]  Qing Cao,et al.  An improved model for fragment-based lead generation at AstraZeneca. , 2016, Drug discovery today.

[12]  Jonas Boström,et al.  Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? , 2016, Journal of medicinal chemistry.

[13]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[14]  Meir Glick,et al.  Construction of a 3D-shaped, natural product like fragment library by fragmentation and diversification of natural products. , 2017, Bioorganic & medicinal chemistry.

[15]  M. Esteller,et al.  Bromodomain inhibitors and cancer therapy: From structures to applications , 2016, Epigenetics.

[16]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[17]  A. Mapp,et al.  Fine-tuning multiprotein complexes using small molecules. , 2012, ACS chemical biology.

[18]  Stephen J Haggarty,et al.  Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. , 2016, ACS medicinal chemistry letters.

[19]  A. Leach,et al.  Molecular complexity and fragment-based drug discovery: ten years on. , 2011, Current opinion in chemical biology.

[20]  Stefan Knapp,et al.  The bromodomain interaction module , 2012, FEBS letters.

[21]  Monya Baker,et al.  Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.

[22]  P. Clemons,et al.  Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.

[23]  N. Mishra,et al.  Protein-observed 19F-NMR for fragment screening, affinity quantification and druggability assessment , 2016, Nature Protocols.

[24]  Y. Leblanc,et al.  Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637). , 2016, ACS medicinal chemistry letters.